<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01155466</url>
  </required_header>
  <id_info>
    <org_study_id>P04938</org_study_id>
    <secondary_id>2009-015161-31</secondary_id>
    <secondary_id>CTRI/2011/07/001896</secondary_id>
    <secondary_id>MK-3814-015</secondary_id>
    <nct_id>NCT01155466</nct_id>
  </id_info>
  <brief_title>A Placebo- and Active Controlled Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (P04938)</brief_title>
  <official_title>A Phase 3, 12-Week, Double-Blind, Double-Dummy, Placebo- and Active-Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Phase 3;Protocol No. P04938)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      When a patient with Parkinson's disease (PD) is initially treated with L-dopa or dopamine
      agonists, the symptoms of PD improve or disappear. After several years of taking L dopa or
      dopamine agonists, patients notice that their PD medications wear off sooner than when they
      first started taking them. This &quot;wearing off&quot; is characterized by the return of symptoms
      (i.e., tremor, slowness, and rigidity) and may occur over the course of a few minutes to an
      hour. When a patient's PD symptoms have returned, the patient is said to be in the &quot;off&quot;
      state. When the patient takes another dose of medication, and his/her PD symptoms improve or
      resolve, the patient is said to be in the &quot;on&quot; state. Antagonism of adenosine Type 2a
      receptors (A2a) may provide relief of PD symptoms. This trial will test the hypothesis that
      A2a receptor antagonism can lead to improvement in the function of PD participants taking a
      stable dose of L-dopa, as measured by a reduction in &quot;off&quot; time.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 14, 2010</start_date>
  <completion_date type="Actual">December 20, 2012</completion_date>
  <primary_completion_date type="Actual">December 20, 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Mean &quot;Off&quot; Time</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The &quot;on&quot; state is defined as the period of time during which a patient's symptoms of PD improve or disappear following treatment with L-dopa or dopamine agonists. The &quot;off&quot; state is defined as the period of time characterized by the return of symptoms (i..e. tremor, slowness, and rigidity) following treatment with L-dopa or dopamine agonists. Study participants reported their symptoms at half-hour intervals as &quot;off&quot;, &quot;on&quot;, or &quot;asleep&quot; on their daily diary for 3 days before randomization (baseline) and for the 3 days immediately before their Week-12 visit. The mean change from baseline in &quot;off&quot; time was based on a constrained longitudinal data analysis with treatment, time, and treatment-by-time interaction as fixed effects and subject as random effect.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Numberof Participants With Systolic Blood Pressure &gt;=180 mm Hg</measure>
    <time_frame>Up to Week 14</time_frame>
    <description>The number of participants with Systolic Blood Pressure &gt;=180 mm Hg was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Diastolic Blood Pressure &gt;=105 mm Hg</measure>
    <time_frame>Up to Week 14</time_frame>
    <description>The number of participants with Diastolic Blood Pressure &gt;=105 mm Hg was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Alanine Aminotransferase &gt;=3 Times the Upper Limit of Normal</measure>
    <time_frame>Up to Week 14</time_frame>
    <description>The number of participants with alanine aminotransferase &gt;=3 times the upper limit of normal and a &gt;=10% increase was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Aspartate Aminotransferase &gt;=3 Times the Upper Limit of Normal</measure>
    <time_frame>Up to Week 14</time_frame>
    <description>The number of participants with aspartate aminotransferase &gt;=3 times the upper limit of normal and a &gt;=10% increase was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Suicidality</measure>
    <time_frame>Up to Week 12</time_frame>
    <description>The percentage of participants with suicidality using the Columbia - Suicide Severity Rating Scale (C-SSRS) was reported. The C-SSR was used in this study only for the purpose of safety monitoring by measuring the incidence of different types of suicidality categories during treatment. The assessment was done by the nature of the responses, not by a numbered scale. Participants who reported at least one occurrence of suicidal behavior or suicidal ideation were counted as having experienced suicidality. Suicidal behavior included suicide attempt, aborted attempt, interrupted attempt, or preparatory behavior. Suicidal ideation included a wish to die or active suicidal thought with or without method, intent or plan.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline at Week 12 in Epworth Sleepiness Scale (ESS)</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The ESS is a self-administered questionnaire providing a measure of a person's general level of daytime sleepiness, or their average sleep propensity in daily life. The scale consists of 8 situations in which the participant rates their tendency to become sleepy on a scale of 0=no chance of dozing to 3=high chance of dozing. The overall score is the sum of the scores for the 8 situations for a minimum of 0 and a maximum of 24.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With &gt;30% Change (Reduction) From Baseline at Week 12 in Mean &quot;Off&quot; Time</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The &quot;on&quot; state is defined as the period of time during which a patient's symptoms of PD improve or disappear following treatment with L-dopa or dopamine agonists. The &quot;off&quot; state is defined as the period of time characterized by the return of symptoms (i..e. tremor, slowness, and rigidity) following treatment with L-dopa or dopamine agonists. Study participants reported their symptoms at half-hour intervals as &quot;off&quot;, &quot;on&quot;, or &quot;asleep&quot; on their daily diary for 3 days before randomization and for the 3 days immediately before their Week-12 visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline at Week 12 in Mean &quot;On&quot; Time Without Troublesome Dyskinesia</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>When a participant is &quot;on&quot; without dyskinesias, parkinsonian symptoms have dissipated and the participant is experiencing no uncontrollable extraneous movements. Study participants reported their parkinsonian symptoms at half-hour intervals as &quot;off&quot;, &quot;on without dyskinesia&quot;, &quot;on with non-troublesome dyskinesia&quot;, &quot;on with troublesome dyskinesia&quot;, or &quot;asleep&quot; on their daily diary for 3 days before randomization and for the 3 days immediately before their Week-12 visit. The mean change from baseline in &quot;on without troublesome dyskinesia&quot; time was based on a constrained longitudinal data analysis with treatment, time, and treatment-by-time interaction as fixed effects and subject as random effect.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">778</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Preladenant 2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Preladenant 2 mg tablet + placebo to rasagiline capsule in AM and preladenant 2 mg tablet in PM for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Preladenant 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Preladenant 5 mg tablet + placebo to rasagiline capsule in AM and preladenant 5 mg tablet in PM for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Preladenant 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Preladenant 10 mg tablet + placebo to rasagiline capsule in AM and preladenant 10 mg tablet in PM for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to preladenant tablet + placebo to rasagiline capsule in AM and placebo to preladenant tablet in PM for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rasagiline 1 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rasagiline 1 mg capsule + placebo to preladenant tablet in AM and placebo to preladenant tablet in PM for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Preladenant 2 mg tablet</intervention_name>
    <description>one 2 mg tablet orally twice daily</description>
    <arm_group_label>Preladenant 2 mg</arm_group_label>
    <other_name>SCH 420814</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Preladenant 5 mg tablet</intervention_name>
    <description>one 5 mg tablet orally twice daily</description>
    <arm_group_label>Preladenant 5 mg</arm_group_label>
    <other_name>SCH 420814</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Preladenant 10 mg tablet</intervention_name>
    <description>one 10 mg tablet orally twice daily</description>
    <arm_group_label>Preladenant 10 mg</arm_group_label>
    <other_name>SCH 420814</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to Preladenant Tablet</intervention_name>
    <description>one tablet orally twice daily</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Rasagiline 1 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rasagiline 1 mg capsule</intervention_name>
    <description>one 1 mg capsule orally in AM</description>
    <arm_group_label>Rasagiline 1 mg</arm_group_label>
    <other_name>Azilect</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to Rasagiline capsule</intervention_name>
    <description>one capsule orally in AM</description>
    <arm_group_label>Preladenant 2 mg</arm_group_label>
    <arm_group_label>Preladenant 5 mg</arm_group_label>
    <arm_group_label>Preladenant 10 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must have a diagnosis of moderate to severe idiopathic Parkinson's disease.

          -  Must have received prior therapy with L dopa for approximately 1 or more years
             immediately before Screening and must continue to have a beneficial clinical response
             to L dopa

          -  Must have been on a stable dopaminergic treatment regimen for at least the 5 weeks
             immediately before Randomization. Participants receiving other adjunctive treatments
             (eg, dopamine agonists, anticholinergics, entacapone) or taking only L dopa are
             permitted, provided the treatment regimen has been taken for at least 5 weeks prior to
             randomization

          -  Must be experiencing motor fluctuations with or without dyskinesias within the 4 weeks
             immediately before Screening, must be experiencing a minimum of 2 hours/day of &quot;off&quot;
             time, and have a Hoehn &amp; Yahr stage between 2.5 and 4 when in the &quot;on&quot; state

          -  Must be capable of maintaining an accurate and complete symptom diary and to adhere to
             dose and visit schedules with or without the help of a caregiver

          -  Must have results of a physical examination and screening clinical laboratory tests
             clinically acceptable to the investigator

          -  If sexually active or plan to be sexually active agree to use a highly effective
             method of birth control while in the study and for 2 weeks after the last dose of
             study drug. Males must also not donate sperm during the trial within 2 weeks after the
             last dose of study drug

        Exclusion Criteria:

          -  Must not have a form of drug induced or atypical parkinsonism, a cognitive impairment,
             bipolar disorder, untreated major depressive disorder, schizophrenia, or other
             psychotic disorder; history of exposure to a known neurotoxin, or any neurological
             features not consistent with the diagnosis of PD as assessed by the investigator

          -  Must not have a history of repeated strokes or head injuries, or a stroke within 6
             months of Screening

          -  Must not have poorly-controlled diabetes or abnormal renal function

          -  Must not have had surgery for their PD

          -  Must not be at imminent risk of self-harm or harm to others

          -  Must not have sleep attacks or compulsive behavior that would interfere with the
             integrity of the trial or would pose a risk to the subject in participating in the
             trial

          -  Must not have a systolic blood pressure (BP) ≥150 mm Hg OR diastolic BP ≥95 mm Hg at
             Screening

          -  Must not have had any clinically significant cardiovascular event or procedure for 6
             months prior to study start, including, but not limited to, myocardial infarction,
             angioplasty, unstable angina, or heart failure; and must not have heart failure staged
             New York Heart Association Class III or IV

          -  Must not have an alanine aminotransferase (ALT) or aspartate amino transferase (AST)
             ≥3 x the upper limit of normal (ULN) or total bilirubin (T-BIL) ≥1.5 x ULN

          -  Must not have a history of serologically confirmed hepatic dysfunction (defined as
             viral infection [Hepatitis B or C; Epstein Barr virus (EBV); cytomegalovirus (CMV)])
             or a history of diagnosis of drug or alcohol induced hepatic toxicity or frank
             hepatitis

          -  Must not have a history within the past 5 years of a primary or recurrent malignant
             disease with the exception of adequately treated basal cell or squamous cell skin
             cancer, in situ cervical cancer, or in situ prostate cancer with a normal
             prostate-specific antigen (PSA) post resection

          -  Must not have received certain prespecified medications or ingested high
             tyramine-containing aged cheeses (eg, Stilton) for a prespecified time window before
             the trial, during the trial, and for 2 weeks after the trial

          -  Must not have an average daily consumption of more than three 4 ounce glasses (118 mL)
             of wine or the equivalent

          -  Must not have a severe or ongoing unstable medical condition (eg, any form of
             clinically significant cardiac disease, symptomatic orthostatic hypotension, seizures,
             or alcohol/drug dependence)

          -  Must not have allergy/sensitivity to investigational product(s) or its/their
             excipients

          -  A female subject must not be breast-feeding, considering breast-feeding, pregnant, or
             intending to become pregnant

          -  Must not have used preladenant ever, or any investigational drugs within 90 days
             immediately before Screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Austria</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>India</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Netherlands</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Hauser RA, Stocchi F, Rascol O, Huyck SB, Capece R, Ho TW, Sklar P, Lines C, Michelson D, Hewitt D. Preladenant as an Adjunctive Therapy With Levodopa in Parkinson Disease: Two Randomized Clinical Trials and Lessons Learned. JAMA Neurol. 2015 Dec;72(12):1491-500. doi: 10.1001/jamaneurol.2015.2268.</citation>
    <PMID>26523919</PMID>
  </results_reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2010</study_first_submitted>
  <study_first_submitted_qc>June 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2010</study_first_posted>
  <results_first_submitted>January 13, 2016</results_first_submitted>
  <results_first_submitted_qc>January 13, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 11, 2016</results_first_posted>
  <last_update_submitted>June 2, 2017</last_update_submitted>
  <last_update_submitted_qc>June 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Idiopathic Parkinson Disease</keyword>
  <keyword>Idiopathic Parkinson's Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rasagiline</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/study.html?id=P04938&amp;kw=P04938&amp;tab=access</doc_url>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total 1076 participants were screened and 778 were randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Preladenant 2 mg</title>
          <description>Preladenant 2 mg tablet + placebo to rasagiline capsule in AM and preladenant 2 mg tablet in PM for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>Preladenant 5 mg</title>
          <description>Preladenant 5 mg tablet + placebo to rasagiline capsule in AM and preladenant 5 mg tablet in PM for 12 weeks</description>
        </group>
        <group group_id="P3">
          <title>Preladenant 10 mg</title>
          <description>Preladenant 10 mg tablet + placebo to rasagiline capsule in AM and preladenant 10 mg tablet in PM for 12 weeks</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Placebo to preladenant tablet + placebo to rasagiline capsule in AM and placebo to preladenant tablet in PM for 12 weeks</description>
        </group>
        <group group_id="P5">
          <title>Rasagiline 1 mg</title>
          <description>Rasagiline 1 mg capsule + placebo to preladenant tablet in AM and placebo to preladenant tablet in PM for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="156"/>
                <participants group_id="P2" count="155"/>
                <participants group_id="P3" count="156"/>
                <participants group_id="P4" count="155"/>
                <participants group_id="P5" count="156"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="154"/>
                <participants group_id="P2" count="153"/>
                <participants group_id="P3" count="153"/>
                <participants group_id="P4" count="155"/>
                <participants group_id="P5" count="154"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="134">Completed treatment phase</participants>
                <participants group_id="P2" count="130">Completed treatment phase</participants>
                <participants group_id="P3" count="136">Completed treatment phase</participants>
                <participants group_id="P4" count="134">Completed treatment phase</participants>
                <participants group_id="P5" count="129">Completed treatment phase</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="21"/>
                <participants group_id="P5" count="27"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="17"/>
                <participants group_id="P5" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized not treated</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants</population>
      <group_list>
        <group group_id="B1">
          <title>Preladenant 2 mg</title>
          <description>Preladenant 2 mg tablet + placebo to rasagiline capsule in AM and preladenant 2 mg tablet in PM for 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>Preladenant 5 mg</title>
          <description>Preladenant 5 mg tablet + placebo to rasagiline capsule in AM and preladenant 5 mg tablet in PM for 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>Preladenant 10 mg</title>
          <description>Preladenant 10 mg tablet + placebo to rasagiline capsule in AM and preladenant 10 mg tablet in PM for 12 weeks</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Placebo to preladenant tablet + placebo to rasagiline capsule in AM and placebo to preladenant tablet in PM for 12 weeks</description>
        </group>
        <group group_id="B5">
          <title>Rasagiline 1 mg</title>
          <description>Rasagiline 1 mg capsule + placebo to preladenant tablet in AM and placebo to preladenant tablet in PM for 12 weeks</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="156"/>
            <count group_id="B2" value="155"/>
            <count group_id="B3" value="156"/>
            <count group_id="B4" value="155"/>
            <count group_id="B5" value="156"/>
            <count group_id="B6" value="778"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.7" spread="9.2"/>
                    <measurement group_id="B2" value="62.6" spread="8.5"/>
                    <measurement group_id="B3" value="63.6" spread="8.4"/>
                    <measurement group_id="B4" value="63.0" spread="8.4"/>
                    <measurement group_id="B5" value="63.8" spread="9.0"/>
                    <measurement group_id="B6" value="62.9" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="61"/>
                    <measurement group_id="B4" value="77"/>
                    <measurement group_id="B5" value="61"/>
                    <measurement group_id="B6" value="332"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="99"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="95"/>
                    <measurement group_id="B4" value="78"/>
                    <measurement group_id="B5" value="95"/>
                    <measurement group_id="B6" value="446"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Mean &quot;Off&quot; Time</title>
        <description>The &quot;on&quot; state is defined as the period of time during which a patient's symptoms of PD improve or disappear following treatment with L-dopa or dopamine agonists. The &quot;off&quot; state is defined as the period of time characterized by the return of symptoms (i..e. tremor, slowness, and rigidity) following treatment with L-dopa or dopamine agonists. Study participants reported their symptoms at half-hour intervals as &quot;off&quot;, &quot;on&quot;, or &quot;asleep&quot; on their daily diary for 3 days before randomization (baseline) and for the 3 days immediately before their Week-12 visit. The mean change from baseline in &quot;off&quot; time was based on a constrained longitudinal data analysis with treatment, time, and treatment-by-time interaction as fixed effects and subject as random effect.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>The number of randomized and treated participants with at least one post baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>Preladenant 2 mg</title>
            <description>Preladenant 2 mg tablet + placebo to rasagiline capsule in AM and preladenant 2 mg tablet in PM for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Preladenant 5 mg</title>
            <description>Preladenant 5 mg tablet + placebo to rasagiline capsule in AM and preladenant 5 mg tablet in PM for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Preladenant 10 mg</title>
            <description>Preladenant 10 mg tablet + placebo to rasagiline capsule in AM and preladenant 10 mg tablet in PM for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo to preladenant tablet + placebo to rasagiline capsule in AM and placebo to preladenant tablet in PM for 12 weeks</description>
          </group>
          <group group_id="O5">
            <title>Rasagiline 1 mg</title>
            <description>Rasagiline 1 mg capsule + placebo to preladenant tablet in AM and placebo to preladenant tablet in PM for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean &quot;Off&quot; Time</title>
          <description>The &quot;on&quot; state is defined as the period of time during which a patient's symptoms of PD improve or disappear following treatment with L-dopa or dopamine agonists. The &quot;off&quot; state is defined as the period of time characterized by the return of symptoms (i..e. tremor, slowness, and rigidity) following treatment with L-dopa or dopamine agonists. Study participants reported their symptoms at half-hour intervals as &quot;off&quot;, &quot;on&quot;, or &quot;asleep&quot; on their daily diary for 3 days before randomization (baseline) and for the 3 days immediately before their Week-12 visit. The mean change from baseline in &quot;off&quot; time was based on a constrained longitudinal data analysis with treatment, time, and treatment-by-time interaction as fixed effects and subject as random effect.</description>
          <population>The number of randomized and treated participants with at least one post baseline value.</population>
          <units>Hours/day</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="149"/>
                <count group_id="O4" value="151"/>
                <count group_id="O5" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="0.21"/>
                    <measurement group_id="O2" value="-0.9" spread="0.21"/>
                    <measurement group_id="O3" value="-0.8" spread="0.21"/>
                    <measurement group_id="O4" value="-0.8" spread="0.21"/>
                    <measurement group_id="O5" value="-1.1" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8700</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.62</ci_lower_limit>
            <ci_upper_limit>0.53</ci_upper_limit>
            <estimate_desc>The estimated parameter is the difference in the estimated mean change from baseline in mean &quot;off&quot; time for preladenant 10 mg - placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Numberof Participants With Systolic Blood Pressure &gt;=180 mm Hg</title>
        <description>The number of participants with Systolic Blood Pressure &gt;=180 mm Hg was reported.</description>
        <time_frame>Up to Week 14</time_frame>
        <population>The number of participants who received at least one dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Preladenant 2 mg</title>
            <description>Preladenant 2 mg tablet + placebo to rasagiline capsule in AM and preladenant 2 mg tablet in PM for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Preladenant 5 mg</title>
            <description>Preladenant 5 mg tablet + placebo to rasagiline capsule in AM and preladenant 5 mg tablet in PM for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Preladenant 10 mg</title>
            <description>Preladenant 10 mg tablet + placebo to rasagiline capsule in AM and preladenant 10 mg tablet in PM for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo to preladenant tablet + placebo to rasagiline capsule in AM and placebo to preladenant tablet in PM for 12 weeks</description>
          </group>
          <group group_id="O5">
            <title>Rasagiline 1 mg</title>
            <description>Rasagiline 1 mg capsule + placebo to preladenant tablet in AM and placebo to preladenant tablet in PM for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Numberof Participants With Systolic Blood Pressure &gt;=180 mm Hg</title>
          <description>The number of participants with Systolic Blood Pressure &gt;=180 mm Hg was reported.</description>
          <population>The number of participants who received at least one dose of study drug</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="153"/>
                <count group_id="O3" value="153"/>
                <count group_id="O4" value="155"/>
                <count group_id="O5" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="0.21"/>
                    <measurement group_id="O2" value="1" spread="0.21"/>
                    <measurement group_id="O3" value="3" spread="0.21"/>
                    <measurement group_id="O4" value="1" spread="0.21"/>
                    <measurement group_id="O5" value="0" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Diastolic Blood Pressure &gt;=105 mm Hg</title>
        <description>The number of participants with Diastolic Blood Pressure &gt;=105 mm Hg was reported.</description>
        <time_frame>Up to Week 14</time_frame>
        <population>The number of participants who received at least one dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Preladenant 2 mg</title>
            <description>Preladenant 2 mg tablet + placebo to rasagiline capsule in AM and preladenant 2 mg tablet in PM for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Preladenant 5 mg</title>
            <description>Preladenant 5 mg tablet + placebo to rasagiline capsule in AM and preladenant 5 mg tablet in PM for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Preladenant 10 mg</title>
            <description>Preladenant 10 mg tablet + placebo to rasagiline capsule in AM and preladenant 10 mg tablet in PM for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo to preladenant tablet + placebo to rasagiline capsule in AM and placebo to preladenant tablet in PM for 12 weeks</description>
          </group>
          <group group_id="O5">
            <title>Rasagiline 1 mg</title>
            <description>Rasagiline 1 mg capsule + placebo to preladenant tablet in AM and placebo to preladenant tablet in PM for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Diastolic Blood Pressure &gt;=105 mm Hg</title>
          <description>The number of participants with Diastolic Blood Pressure &gt;=105 mm Hg was reported.</description>
          <population>The number of participants who received at least one dose of study drug</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="153"/>
                <count group_id="O3" value="153"/>
                <count group_id="O4" value="155"/>
                <count group_id="O5" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" spread="0.21"/>
                    <measurement group_id="O2" value="4" spread="0.21"/>
                    <measurement group_id="O3" value="9" spread="0.21"/>
                    <measurement group_id="O4" value="7" spread="0.21"/>
                    <measurement group_id="O5" value="4" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.899</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-2.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.3</ci_lower_limit>
            <ci_upper_limit>1.6</ci_upper_limit>
            <estimate_desc>The estimated parameter is the difference in the percentage of participants with diastolic blood pressure &gt;=105 mm Hg for preladenant 2 mg - placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.815</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-1.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.8</ci_lower_limit>
            <ci_upper_limit>2.6</ci_upper_limit>
            <estimate_desc>The estimated parameter is the difference in the percentage of participants with diastolic blood pressure &gt;=105 mm Hg for preladenant 5 mg - placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.295</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.9</ci_lower_limit>
            <ci_upper_limit>6.9</ci_upper_limit>
            <estimate_desc>The estimated parameter is the difference in the percentage of participants with diastolic blood pressure &gt;=105 mm Hg for preladenant 10 mg - placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Alanine Aminotransferase &gt;=3 Times the Upper Limit of Normal</title>
        <description>The number of participants with alanine aminotransferase &gt;=3 times the upper limit of normal and a &gt;=10% increase was reported.</description>
        <time_frame>Up to Week 14</time_frame>
        <population>The number of participants who received at least one dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Preladenant 2 mg</title>
            <description>Preladenant 2 mg tablet + placebo to rasagiline capsule in AM and preladenant 2 mg tablet in PM for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Preladenant 5 mg</title>
            <description>Preladenant 5 mg tablet + placebo to rasagiline capsule in AM and preladenant 5 mg tablet in PM for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Preladenant 10 mg</title>
            <description>Preladenant 10 mg tablet + placebo to rasagiline capsule in AM and preladenant 10 mg tablet in PM for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo to preladenant tablet + placebo to rasagiline capsule in AM and placebo to preladenant tablet in PM for 12 weeks</description>
          </group>
          <group group_id="O5">
            <title>Rasagiline 1 mg</title>
            <description>Rasagiline 1 mg capsule + placebo to preladenant tablet in AM and placebo to preladenant tablet in PM for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Alanine Aminotransferase &gt;=3 Times the Upper Limit of Normal</title>
          <description>The number of participants with alanine aminotransferase &gt;=3 times the upper limit of normal and a &gt;=10% increase was reported.</description>
          <population>The number of participants who received at least one dose of study drug</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="153"/>
                <count group_id="O3" value="153"/>
                <count group_id="O4" value="155"/>
                <count group_id="O5" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="0.21"/>
                    <measurement group_id="O2" value="1" spread="0.21"/>
                    <measurement group_id="O3" value="1" spread="0.21"/>
                    <measurement group_id="O4" value="1" spread="0.21"/>
                    <measurement group_id="O5" value="0" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Aspartate Aminotransferase &gt;=3 Times the Upper Limit of Normal</title>
        <description>The number of participants with aspartate aminotransferase &gt;=3 times the upper limit of normal and a &gt;=10% increase was reported.</description>
        <time_frame>Up to Week 14</time_frame>
        <population>The number of participants who received at least one dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Preladenant 2 mg</title>
            <description>Preladenant 2 mg tablet + placebo to rasagiline capsule in AM and preladenant 2 mg tablet in PM for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Preladenant 5 mg</title>
            <description>Preladenant 5 mg tablet + placebo to rasagiline capsule in AM and preladenant 5 mg tablet in PM for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Preladenant 10 mg</title>
            <description>Preladenant 10 mg tablet + placebo to rasagiline capsule in AM and preladenant 10 mg tablet in PM for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo to preladenant tablet + placebo to rasagiline capsule in AM and placebo to preladenant tablet in PM for 12 weeks</description>
          </group>
          <group group_id="O5">
            <title>Rasagiline 1 mg</title>
            <description>Rasagiline 1 mg capsule + placebo to preladenant tablet in AM and placebo to preladenant tablet in PM for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Aspartate Aminotransferase &gt;=3 Times the Upper Limit of Normal</title>
          <description>The number of participants with aspartate aminotransferase &gt;=3 times the upper limit of normal and a &gt;=10% increase was reported.</description>
          <population>The number of participants who received at least one dose of study drug</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="153"/>
                <count group_id="O3" value="153"/>
                <count group_id="O4" value="155"/>
                <count group_id="O5" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="0.21"/>
                    <measurement group_id="O2" value="1" spread="0.21"/>
                    <measurement group_id="O3" value="1" spread="0.21"/>
                    <measurement group_id="O4" value="0" spread="0.21"/>
                    <measurement group_id="O5" value="0" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Suicidality</title>
        <description>The percentage of participants with suicidality using the Columbia - Suicide Severity Rating Scale (C-SSRS) was reported. The C-SSR was used in this study only for the purpose of safety monitoring by measuring the incidence of different types of suicidality categories during treatment. The assessment was done by the nature of the responses, not by a numbered scale. Participants who reported at least one occurrence of suicidal behavior or suicidal ideation were counted as having experienced suicidality. Suicidal behavior included suicide attempt, aborted attempt, interrupted attempt, or preparatory behavior. Suicidal ideation included a wish to die or active suicidal thought with or without method, intent or plan.</description>
        <time_frame>Up to Week 12</time_frame>
        <population>The number of participants who received at least one dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Preladenant 2 mg</title>
            <description>Preladenant 2 mg tablet + placebo to rasagiline capsule in AM and preladenant 2 mg tablet in PM for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Preladenant 5 mg</title>
            <description>Preladenant 5 mg tablet + placebo to rasagiline capsule in AM and preladenant 5 mg tablet in PM for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Preladenant 10 mg</title>
            <description>Preladenant 10 mg tablet + placebo to rasagiline capsule in AM and preladenant 10 mg tablet in PM for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo to preladenant tablet + placebo to rasagiline capsule in AM and placebo to preladenant tablet in PM for 12 weeks</description>
          </group>
          <group group_id="O5">
            <title>Rasagiline 1 mg</title>
            <description>Rasagiline 1 mg capsule + placebo to preladenant tablet in AM and placebo to preladenant tablet in PM for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Suicidality</title>
          <description>The percentage of participants with suicidality using the Columbia - Suicide Severity Rating Scale (C-SSRS) was reported. The C-SSR was used in this study only for the purpose of safety monitoring by measuring the incidence of different types of suicidality categories during treatment. The assessment was done by the nature of the responses, not by a numbered scale. Participants who reported at least one occurrence of suicidal behavior or suicidal ideation were counted as having experienced suicidality. Suicidal behavior included suicide attempt, aborted attempt, interrupted attempt, or preparatory behavior. Suicidal ideation included a wish to die or active suicidal thought with or without method, intent or plan.</description>
          <population>The number of participants who received at least one dose of study drug</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="153"/>
                <count group_id="O3" value="153"/>
                <count group_id="O4" value="155"/>
                <count group_id="O5" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="0.21"/>
                    <measurement group_id="O2" value="2.6" spread="0.21"/>
                    <measurement group_id="O3" value="0.7" spread="0.21"/>
                    <measurement group_id="O4" value="3.2" spread="0.21"/>
                    <measurement group_id="O5" value="0.6" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.629</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.1</ci_lower_limit>
            <ci_upper_limit>3.7</ci_upper_limit>
            <estimate_desc>The estimated parameter is the difference in the percentage of participants with suicidality for preladenant 2 mg - placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.625</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.1</ci_lower_limit>
            <ci_upper_limit>3.7</ci_upper_limit>
            <estimate_desc>The estimated parameter is the difference in the percentage of participants with suicidality for preladenant 5 mg - placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.948</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-2.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.8</ci_lower_limit>
            <ci_upper_limit>0.7</ci_upper_limit>
            <estimate_desc>The estimated parameter is the difference in the percentage of participants with suicidality for preladenant 10 mg - placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline at Week 12 in Epworth Sleepiness Scale (ESS)</title>
        <description>The ESS is a self-administered questionnaire providing a measure of a person’s general level of daytime sleepiness, or their average sleep propensity in daily life. The scale consists of 8 situations in which the participant rates their tendency to become sleepy on a scale of 0=no chance of dozing to 3=high chance of dozing. The overall score is the sum of the scores for the 8 situations for a minimum of 0 and a maximum of 24.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>The number of participants who received at least one dose of study drug and had baseline and Week 12 data</population>
        <group_list>
          <group group_id="O1">
            <title>Preladenant 2 mg</title>
            <description>Preladenant 2 mg tablet + placebo to rasagiline capsule in AM and preladenant 2 mg tablet in PM for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Preladenant 5 mg</title>
            <description>Preladenant 5 mg tablet + placebo to rasagiline capsule in AM and preladenant 5 mg tablet in PM for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Preladenant 10 mg</title>
            <description>Preladenant 10 mg tablet + placebo to rasagiline capsule in AM and preladenant 10 mg tablet in PM for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo to preladenant tablet + placebo to rasagiline capsule in AM and placebo to preladenant tablet in PM for 12 weeks</description>
          </group>
          <group group_id="O5">
            <title>Rasagiline 1 mg</title>
            <description>Rasagiline 1 mg capsule + placebo to preladenant tablet in AM and placebo to preladenant tablet in PM for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at Week 12 in Epworth Sleepiness Scale (ESS)</title>
          <description>The ESS is a self-administered questionnaire providing a measure of a person’s general level of daytime sleepiness, or their average sleep propensity in daily life. The scale consists of 8 situations in which the participant rates their tendency to become sleepy on a scale of 0=no chance of dozing to 3=high chance of dozing. The overall score is the sum of the scores for the 8 situations for a minimum of 0 and a maximum of 24.</description>
          <population>The number of participants who received at least one dose of study drug and had baseline and Week 12 data</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="121"/>
                <count group_id="O3" value="132"/>
                <count group_id="O4" value="127"/>
                <count group_id="O5" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="3.4"/>
                    <measurement group_id="O2" value="-0.1" spread="3.1"/>
                    <measurement group_id="O3" value="0.0" spread="3.5"/>
                    <measurement group_id="O4" value="-0.3" spread="3.1"/>
                    <measurement group_id="O5" value="0.1" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7044</p_value>
            <method>Constrained longitudinal data analysis</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.61</ci_lower_limit>
            <ci_upper_limit>0.90</ci_upper_limit>
            <estimate_desc>The estimated parameter is the difference in the change from baseline in mean ESS score for preladenant 2 mg - placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3439</p_value>
            <method>Constrained longitudinal data analysis</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
            <estimate_desc>The estimated parameter is the difference in the change from baseline in mean ESS score for preladenant 5 mg - placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3941</p_value>
            <method>Constrained longitudinal data analysis</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.43</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
            <estimate_desc>The estimated parameter is the difference in the change from baseline in mean ESS score for preladenant 10 mg - placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With &gt;30% Change (Reduction) From Baseline at Week 12 in Mean &quot;Off&quot; Time</title>
        <description>The &quot;on&quot; state is defined as the period of time during which a patient's symptoms of PD improve or disappear following treatment with L-dopa or dopamine agonists. The &quot;off&quot; state is defined as the period of time characterized by the return of symptoms (i..e. tremor, slowness, and rigidity) following treatment with L-dopa or dopamine agonists. Study participants reported their symptoms at half-hour intervals as &quot;off&quot;, &quot;on&quot;, or &quot;asleep&quot; on their daily diary for 3 days before randomization and for the 3 days immediately before their Week-12 visit.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>The number of randomized and treated participants with a Week 12 value.</population>
        <group_list>
          <group group_id="O1">
            <title>Preladenant 2 mg</title>
            <description>Preladenant 2 mg tablet + placebo to rasagiline capsule in AM and preladenant 2 mg tablet in PM for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Preladenant 5 mg</title>
            <description>Preladenant 5 mg tablet + placebo to rasagiline capsule in AM and preladenant 5 mg tablet in PM for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Preladenant 10 mg</title>
            <description>Preladenant 10 mg tablet + placebo to rasagiline capsule in AM and preladenant 10 mg tablet in PM for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo to preladenant tablet + placebo to rasagiline capsule in AM and placebo to preladenant tablet in PM for 12 weeks</description>
          </group>
          <group group_id="O5">
            <title>Rasagiline 1 mg</title>
            <description>Rasagiline 1 mg capsule + placebo to preladenant tablet in AM and placebo to preladenant tablet in PM for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With &gt;30% Change (Reduction) From Baseline at Week 12 in Mean &quot;Off&quot; Time</title>
          <description>The &quot;on&quot; state is defined as the period of time during which a patient's symptoms of PD improve or disappear following treatment with L-dopa or dopamine agonists. The &quot;off&quot; state is defined as the period of time characterized by the return of symptoms (i..e. tremor, slowness, and rigidity) following treatment with L-dopa or dopamine agonists. Study participants reported their symptoms at half-hour intervals as &quot;off&quot;, &quot;on&quot;, or &quot;asleep&quot; on their daily diary for 3 days before randomization and for the 3 days immediately before their Week-12 visit.</description>
          <population>The number of randomized and treated participants with a Week 12 value.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="122"/>
                <count group_id="O3" value="131"/>
                <count group_id="O4" value="131"/>
                <count group_id="O5" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.4"/>
                    <measurement group_id="O2" value="33.6"/>
                    <measurement group_id="O3" value="35.1"/>
                    <measurement group_id="O4" value="32.8"/>
                    <measurement group_id="O5" value="33.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.983</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Odds ratio was calculated for all randomized and treated participants with at least 1 post treatment value.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.994</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.597</ci_lower_limit>
            <ci_upper_limit>1.657</ci_upper_limit>
            <estimate_desc>Confidence intervals and P-values were based on a generalized linear mixed model with baseline average &quot;off&quot; time as a covariate and treatment-by-time interaction as fixed effect and participant as random effect.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline at Week 12 in Mean &quot;On&quot; Time Without Troublesome Dyskinesia</title>
        <description>When a participant is &quot;on&quot; without dyskinesias, parkinsonian symptoms have dissipated and the participant is experiencing no uncontrollable extraneous movements. Study participants reported their parkinsonian symptoms at half-hour intervals as &quot;off&quot;, &quot;on without dyskinesia&quot;, &quot;on with non-troublesome dyskinesia&quot;, &quot;on with troublesome dyskinesia&quot;, or &quot;asleep&quot; on their daily diary for 3 days before randomization and for the 3 days immediately before their Week-12 visit. The mean change from baseline in &quot;on without troublesome dyskinesia&quot; time was based on a constrained longitudinal data analysis with treatment, time, and treatment-by-time interaction as fixed effects and subject as random effect.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>The number of randomized and treated participants with at least one post baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>Preladenant 2 mg</title>
            <description>Preladenant 2 mg tablet + placebo to rasagiline capsule in AM and preladenant 2 mg tablet in PM for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Preladenant 5 mg</title>
            <description>Preladenant 5 mg tablet + placebo to rasagiline capsule in AM and preladenant 5 mg tablet in PM for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Preladenant 10 mg</title>
            <description>Preladenant 10 mg tablet + placebo to rasagiline capsule in AM and preladenant 10 mg tablet in PM for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo to preladenant tablet + placebo to rasagiline capsule in AM and placebo to preladenant tablet in PM for 12 weeks</description>
          </group>
          <group group_id="O5">
            <title>Rasagiline 1 mg</title>
            <description>Rasagiline 1 mg capsule + placebo to preladenant tablet in AM and placebo to preladenant tablet in PM for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at Week 12 in Mean &quot;On&quot; Time Without Troublesome Dyskinesia</title>
          <description>When a participant is &quot;on&quot; without dyskinesias, parkinsonian symptoms have dissipated and the participant is experiencing no uncontrollable extraneous movements. Study participants reported their parkinsonian symptoms at half-hour intervals as &quot;off&quot;, &quot;on without dyskinesia&quot;, &quot;on with non-troublesome dyskinesia&quot;, &quot;on with troublesome dyskinesia&quot;, or &quot;asleep&quot; on their daily diary for 3 days before randomization and for the 3 days immediately before their Week-12 visit. The mean change from baseline in &quot;on without troublesome dyskinesia&quot; time was based on a constrained longitudinal data analysis with treatment, time, and treatment-by-time interaction as fixed effects and subject as random effect.</description>
          <population>The number of randomized and treated participants with at least one post baseline value.</population>
          <units>Hours/day</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="149"/>
                <count group_id="O4" value="151"/>
                <count group_id="O5" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.24"/>
                    <measurement group_id="O2" value="0.9" spread="0.24"/>
                    <measurement group_id="O3" value="0.5" spread="0.23"/>
                    <measurement group_id="O4" value="0.4" spread="0.24"/>
                    <measurement group_id="O5" value="0.7" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6405</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.49</ci_lower_limit>
            <ci_upper_limit>0.80</ci_upper_limit>
            <estimate_desc>The estimated parameter is the difference in the estimated change from baseline in &quot;on&quot; time without troublesome dyskinesias for preladenant 10 mg - placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All adverse events: up to Week 14; serious adverse events: up to 30 days after the last dose of study drug (up to Week 16)</time_frame>
      <desc>The safety population included all participants who received at least one dose of study drug</desc>
      <group_list>
        <group group_id="E1">
          <title>Preladenant 2 mg</title>
          <description>Preladenant 2 mg tablet + placebo to rasagiline capsule in AM and preladenant 2 mg tablet in PM for 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>Preladenant 5 mg</title>
          <description>Preladenant 5 mg tablet + placebo to rasagiline capsule in AM and preladenant 5 mg tablet in PM for 12 weeks</description>
        </group>
        <group group_id="E3">
          <title>Preladenant 10 mg</title>
          <description>Preladenant 10 mg tablet + placebo to rasagiline capsule in AM and preladenant 10 mg tablet in PM for 12 weeks</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Placebo to preladenant tablet + placebo to rasagiline capsule in AM and placebo to preladenant tablet in PM for 12 weeks</description>
        </group>
        <group group_id="E5">
          <title>Rasagiline 1 mg</title>
          <description>Rasagiline 1 mg capsule + placebo to preladenant tablet in AM and placebo to preladenant tablet in PM for 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="153"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="155"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Gilbert's syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Periproctitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthermia malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Malignant melanoma stage IV</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Oesophageal adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Parkinsonism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Delusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Hallucination, auditory</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Paranoia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Pulmonary infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA version 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="153"/>
                <counts group_id="E4" subjects_affected="34" subjects_at_risk="155"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="154"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="153"/>
                <counts group_id="E3" events="17" subjects_affected="16" subjects_at_risk="153"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="154"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="155"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dyskinesia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="154"/>
                <counts group_id="E2" events="13" subjects_affected="10" subjects_at_risk="153"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="153"/>
                <counts group_id="E4" events="9" subjects_affected="8" subjects_at_risk="155"/>
                <counts group_id="E5" events="23" subjects_affected="21" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="154"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="153"/>
                <counts group_id="E4" events="17" subjects_affected="16" subjects_at_risk="155"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="155"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The investigator agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the trial. The sponsor shall have the right to review and comment with respect to publications, abstracts, slides, and manuscripts and the right to review and comment on the data analysis and presentation with regard to proprietary information, accuracy, fair balance, and compliance.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

